Eric Dobmeier - 10 Nov 2023 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Reporting relationship: Director
Issuer ticker: ATRA
Reported as of: 10 Nov 2023
Net transaction value: +$101,340
SEC form: 4
Accepted by SEC: 14 Nov 2023, 18:27:14 UTC
Prior SEC filing: 11 Aug 2023
Next SEC filing: 27 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Jeff Kiekhofer, Attorney-in-Fact

Key filing fact

Eric Dobmeier filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 14 Nov 2023.

Key facts

This page summarizes Eric Dobmeier's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Nov 2023, 18:27.

Change

Previous filing in this sequence was filed on 11 Aug 2023.
Current net transaction value: +$101,340.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA transaction

Common Stock

Purchase

Transaction value: $101,340
Shares: +446,825
Change %: +384%
Price: $0.2268^*
Shares after: 563,325
Date: 10 Nov 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2235 to $0.2298. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.